Varanasi News Magazine

DelveInsight Evaluates a Robust Atopic Dermatitis Pipeline as 100+ Companies to Set Foot in the Domain

 Breaking News
  • No posts were found

DelveInsight Evaluates a Robust Atopic Dermatitis Pipeline as 100+ Companies to Set Foot in the Domain

March 06
20:57 2023
DelveInsight Evaluates a Robust Atopic Dermatitis Pipeline as 100+ Companies to Set Foot in the Domain

DelveInsight’s, “Atopic Dermatitis Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Atopic Dermatitis Emerging drugs, the Atopic Dermatitis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Atopic Dermatitis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Atopic Dermatitis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Atopic Dermatitis clinical trials studies, Atopic Dermatitis NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Atopic Dermatitis Pipeline Report

 

  • DelveInsight’s Atopic Dermatitis Pipeline analysis depicts a robust space with 100+ active players working to develop 100+ pipeline treatment therapies.

 

  • The leading Atopic Dermatitis Companies include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

 

  • Promising Atopic Dermatitis pipeline therapies such as Baricitinib, Lebrikizumab, MEDI9929, and others.

 

  • The Atopic Dermatitis Companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The Atopic Dermatitis pipeline therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.

  

Request a sample and discover the recent breakthroughs happening in the Atopic Dermatitis Pipeline landscape @ Atopic Dermatitis Pipeline Outlook Report

 

Atopic Dermatitis Overview

Atopic dermatitis, often referred to as eczema, is a chronic (long-lasting) disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease. Atopic dermatitis is not contagious, so it cannot be spread from person to person. Atopic dermatitis causes the skin to become extremely itchy. Scratching leads to further redness, swelling, cracking, “weeping” clear fluid, crusting, and scaling. In most cases, there are periods of time when the disease is worse, called flares, followed by periods when the skin improves or clears up entirely, called remissions.

 

Recent Developmental Activities in the Atopic Dermatitis Treatment Landscape

 

  • In November 2022, Alphyn Biologics announced that it had completed the first cohort of its Phase IIa clinical trial of AB-101a, a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old. The first cohort enrolled AD patients without bacterial infection, which is sometimes associated with the disease. Top-line results are expected in approximately eight weeks.

 

  • In September 2022, selectION announced that it has begun dosing patients in a Phase Ib trial to evaluate safety and efficacy, including duration of clinical benefit, of si-544 in patients with mild to severe atopic dermatitis.

 

  • In July 2022, Connect Biopharma Holdings announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration (CDE), that it can conduct primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 to treat adult patients with moderate-to-severe atopic dermatitis (AD) based on the 255 patients. As a result, Connect Biopharma plans to report this trial’s top-line results by year-end, earlier than originally planned.

 

  • In May 2022, Brickell Biotech announced that the first subjects were dosed in the single ascending dose of Phase I clinical trial evaluating BBI-02 in healthy adult subjects and patients with atopic dermatitis. BBI-02 is a potential first-in-class, highly selective, orally bioavailable small molecule DYRK1A inhibitor that aims to restore immune balance through modulating adaptive and innate immune responses in patients with autoimmune and inflammatory diseases.

 

  • In November 2021, The Food and Drug Administration (FDA) granted Fast Track designation to orismilast for the treatment of moderate to severe atopic dermatitis. Orismilast is a selective next generation phosphodiesterase-4 (PDE4) inhibitor with broad anti-inflammatory properties.

  

For further information, refer to the detailed Atopic Dermatitis Drugs Launch, Atopic Dermatitis Developmental Activities, and Atopic Dermatitis News, click here for Atopic Dermatitis Ongoing Clinical Trial Analysis

 

Atopic Dermatitis Emerging Drugs Profiles

 

  • Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

 

  • BX 005: BiomX

BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

 

  • LP 0145: LEO Pharma

LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

 

Atopic Dermatitis Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase II include, LEO Pharma.

 

Find out more about the Atopic Dermatitis Pipeline Segmentation, Therapeutics Assessment, and Atopic Dermatitis Emerging Drugs @ Atopic Dermatitis Treatment Landscape

 

Scope of the Atopic Dermatitis Pipeline Report

 

  • Coverage- Global

 

  • Atopic Dermatitis Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

 

  • Atopic Dermatitis pipeline Therapies- Baricitinib, Lebrikizumab, MEDI9929, and others.

 

  • Atopic Dermatitis Segmentation: Phases, Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Atopic Dermatitis Pipeline Companies and Therapies, click here @ Atopic Dermatitis Unmet Needs and Analyst Views

 

Table of Content 

  1. Introduction
  2. Atopic Dermatitis Executive Summary
  3. Atopic Dermatitis: Overview
  4. Atopic Dermatitis Pipeline Therapeutics
  5. Atopic Dermatitis Therapeutic Assessment
  6. Atopic Dermatitis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Amlitelimab: Kymab
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Atopic Dermatitis Key Companies
  21. Atopic Dermatitis Key Products
  22. Atopic Dermatitis- Unmet Needs
  23. Atopic Dermatitis- Market Drivers and Barriers
  24. Atopic Dermatitis- Future Perspectives and Conclusion
  25. Atopic Dermatitis Analyst Views
  26. Atopic Dermatitis Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Atopic Dermatitis Mergers and acquisitions, Atopic Dermatitis Licensing Activities @ Atopic Dermatitis Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/